Cancer immunotherapy via dendritic cells
By K. Palucka, Jacques Banchereau. Nature Reviews. Cancer, 2012
2,015 citations recorded by the source corpus.
Cancer immunotherapy attempts to harness the power and specificity of the immune system to treat tumours. The molecular identification of human cancer-specific antigens has allowed the development of antigen-specific immunotherapy. In one approach, autologous antigen-specific T cells are expanded ex vivo and then re-infused into patients. Another approach is through vaccination; that is, the provision of an antigen together with an adjuvant to elicit therapeutic T cells in vivo. Owing to their properties, dendritic cells (DCs) are often called 'nature's adjuvants' and thus have become the natural agents for antigen delivery. After four decades of research, it is now clear that DCs are at the centre of the immune system owing to their ability to control both immune tolerance and immunity. Thus, DCs are an essential target in efforts to generate therapeutic immunity against cancer.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/2f57d82d300f74ad9b40b5560cdd5c457021ec31
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Exosome-Based Cell-Cell Communication in the Tumor Microenvironment (2018, background): “…low levels of membrane expression of peptide-MHC-II complexes, presence of immunosuppressive cytokines able to convert DCs into tolerogenic state, hindrances to store live DCs and problems regarding stability management over longer periods (Palucka and Banchereau, 2012; Pitt et al., 2016).”
- Dendritic-cell-based therapeutic cancer vaccines. (2013, methodology): “These studies were initially performed as single treatments, but combination studies are now being assessed with agents such as systemic adjuvants, e.g., poly I:C (Aarntzen et al., 2008; Kalinski et al., 2013; Palucka and Banchereau, 2012; Schuler, 2010).”
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “These include administration of immune-stimulating cytokines such as interferon (IFN) and interleukin-2, active immunization to enhance endogenous immune responses such as dendritic cell (DC)-based vaccination, adoptive cell-transfer therapy using autologous cancer-specific cytotoxic T-cells (CTLs) ”
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies. (2015, background): “In addition, regulatory DCs (expressing CD25, 356 PD-1, PD-L1, IL-10, TGFβ, kynurenine, IDO, cyclooxygenase (Cox)-2, and arginase (Arg)-1) 357 play a significant role in tumor development [143] and therapies directed against t hese cells have 358 also been investigated [144].”
- Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “These properties have driven attempts to develop DC-based vaccines [10].”
- Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2017, background): “0 3 10 (4)) (Figure 3E) was significantly greater in the CL subtype, suggesting that this subtype may benefit from dendritic cell vaccines (Palucka and Banchereau, 2012).”
- Current Approaches of Photothermal Therapy in Treating Cancer Metastasis with Nanotherapeutics (2016, background): “Immunotherapy has been considered as the ultimate approach for cancer treatment, which can be achieved by exploiting the patient’s own immune system to recognize and eliminate cancer cells [65].”
- The microenvironmental landscape of brain tumors (2017, background): “…has largely taken a different tack; as interest for immune checkpoint inhibitors in cancer therapy continues to expand, DC vaccines are likewise gaining significant clinical attention as an alternative strategy to stimulate T cell responses (Anguille et al., 2014; Palucka and Banchereau, 2012).”